Katherine Cheng

Katie Cheng is a partner in the Complex Litigation and Dispute Resolution practice at Goodwin and a member of the firm’s Life Sciences Disputes group and Antitrust and Competition practice. She is an experienced litigator and trial lawyer dedicated to helping clients solve their most complex disputes and works tirelessly to develop creative and efficient strategies designed to lead to successful results.

Katie’s work centers on antitrust, consumer protection, and other high-stakes competitive disputes touching on a wide variety of areas such as complex commercial litigation, contract issues, business torts, and unfair competition. Her practice has a special emphasis on the healthcare, life sciences, and technology sectors, and she has represented companies such as healthcare and technology start-ups, pharmacies, drug manufacturers, and a major health insurer. She particularly enjoys working with clients in concentrated markets and industries experiencing disruption and innovation.

Katie has represented both plaintiffs and defendants before federal courts, state courts, and arbitration panels, in all aspects of litigation, including dispositive motion practice, complex discovery, experts, trial, and appeal. She has also represented clients in connection with third-party subpoenas and inquiries by government regulators. Additionally, she provides pre-litigation counseling and advice and litigation risk analysis.

Katie currently serves as a co-local council leader of Goodwin’s Committee on Racial and Ethnic Diversity (CRED) for the D.C. office.

Katie’s experience includes:

• Representing Teva in defense of several class action cases raising antitrust, Lanham Act, RICO, and other claims involving Teva’s branded multiple sclerosis product, Copaxone
• Representing Cipla USA Inc. in connection with Lanham Act, unfair competition claims, and other business torts regarding false statements made by a competitor
• Representing a Silicon Valley healthcare technology startup in a jury trial and appeal against a pharmacy benefits manager regarding various healthcare, tort, and contract claims
• Representing a school safety software company regarding tort claims asserted in connection with a school shooting
• Represented a real estate company in a jury trial regarding tortious interference by former business partner
• Represented a major healthcare insurer against a private equity-backed provider group regarding antitrust and contract claims, winning the only claims tried before the arbitration panel*
• Represented a newly-public biopharmaceutical company in connection with various securities and litigation issues*
• Represented a major cable provider in a jury trial involving antitrust tying claims, with favorable post-trial decision affirmed on appeal*
• Represented individuals injured in the August 2017 Unite the Right rally in Charlottesville, Virginia against 24 neo-Nazis, white supremacists, and affiliated hate groups who organized and conspired to commit violence at the rally*

*Denotes experience prior to joining Goodwin.

Katie serves on the National Women’s Law Center’s Leadership Advisory Committee. She is also a member of the Asian Pacific American Bar Association of DC and participated in the Leadership Council on Legal Diversity’s 2021 Pathfinder program.

Prior to joining Goodwin, Katie practiced at Boies Schiller Flexner LLP and Latham & Watkins LLP. She also served as a law clerk to the Honorable Alan C. Kay in the United States District Court for the District of Hawaii. During law school, she successfully argued a pro bono appeal before the Ninth Circuit. Prior to law school, she was a paralegal specialist at the U.S. Department of Justice, Federal Programs Branch.

Katie has been recognized multiple times by Best Lawyers as One to Watch in Antitrust Law (2021, 2022, 2023).

• Co-Author, “CMS’s Proposed Rule Improves Prior Authorization Processes,” New York Law Journal, April 12, 2023
• Co-Author, “340B Entities Face Increased Challenges in a Shifting Regulatory and Enforcement Landscape,” MedCity News, August 11, 2022